322 related articles for article (PubMed ID: 17614125)
1. Effect of perioperative venous thromboembolism on survival in ovarian, primary peritoneal, and fallopian tube cancer.
Black D; Iasonos A; Ahmed H; Chi DS; Barakat RR; Abu-Rustum NR
Gynecol Oncol; 2007 Oct; 107(1):66-70. PubMed ID: 17614125
[TBL] [Abstract][Full Text] [Related]
2. Transfusion utilization during adnexal or peritoneal cancer surgery: effects on symptomatic venous thromboembolism and survival.
Abu-Rustum NR; Richard S; Wilton A; Lev G; Sonoda Y; Hensley ML; Gemignani M; Barakat RR; Chi DS
Gynecol Oncol; 2005 Nov; 99(2):320-6. PubMed ID: 16061278
[TBL] [Abstract][Full Text] [Related]
3. The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancer.
Zivanovic O; Eisenhauer EL; Zhou Q; Iasonos A; Sabbatini P; Sonoda Y; Abu-Rustum NR; Barakat RR; Chi DS
Gynecol Oncol; 2008 Feb; 108(2):287-92. PubMed ID: 17996927
[TBL] [Abstract][Full Text] [Related]
4. Role of maximal primary cytoreductive surgery in patients with advanced epithelial ovarian and tubal cancer: Surgical and oncological outcomes. Single institution experience.
Peiretti M; Zanagnolo V; Aletti GD; Bocciolone L; Colombo N; Landoni F; Minig L; Biffi R; Radice D; Maggioni A
Gynecol Oncol; 2010 Nov; 119(2):259-64. PubMed ID: 20800269
[TBL] [Abstract][Full Text] [Related]
5. A contemporary analysis of the ability of preoperative serum CA-125 to predict primary cytoreductive outcome in patients with advanced ovarian, tubal and peritoneal carcinoma.
Chi DS; Zivanovic O; Palayekar MJ; Eisenhauer EL; Abu-Rustum NR; Sonoda Y; Levine DA; Leitao MM; Brown CL; Barakat RR
Gynecol Oncol; 2009 Jan; 112(1):6-10. PubMed ID: 19100916
[TBL] [Abstract][Full Text] [Related]
6. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?
Chi DS; Eisenhauer EL; Lang J; Huh J; Haddad L; Abu-Rustum NR; Sonoda Y; Levine DA; Hensley M; Barakat RR
Gynecol Oncol; 2006 Nov; 103(2):559-64. PubMed ID: 16714056
[TBL] [Abstract][Full Text] [Related]
7. Predictors of surgical outcome and survival among elderly women diagnosed with ovarian and primary peritoneal cancer.
Alphs HH; Zahurak ML; Bristow RE; Díaz-Montes TP
Gynecol Oncol; 2006 Dec; 103(3):1048-53. PubMed ID: 16876237
[TBL] [Abstract][Full Text] [Related]
8. Abdominal carcinomatosis in women with a history of breast cancer.
Garg R; Zahurak ML; Trimble EL; Armstrong DK; Bristow RE
Gynecol Oncol; 2005 Oct; 99(1):65-70. PubMed ID: 15979132
[TBL] [Abstract][Full Text] [Related]
9. Incidence of venous thromboembolism in patients with ovarian cancer undergoing platinum/paclitaxel-containing first-line chemotherapy: an exploratory analysis by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group.
Fotopoulou C; duBois A; Karavas AN; Trappe R; Aminossadati B; Schmalfeldt B; Pfisterer J; Sehouli J;
J Clin Oncol; 2008 Jun; 26(16):2683-9. PubMed ID: 18509180
[TBL] [Abstract][Full Text] [Related]
10. Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach.
Chi DS; Franklin CC; Levine DA; Akselrod F; Sabbatini P; Jarnagin WR; DeMatteo R; Poynor EA; Abu-Rustum NR; Barakat RR
Gynecol Oncol; 2004 Sep; 94(3):650-4. PubMed ID: 15350354
[TBL] [Abstract][Full Text] [Related]
11. Tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer: an updated series.
Shih KK; Chi DS; Barakat RR; Leitao MM
Gynecol Oncol; 2010 May; 117(2):330-5. PubMed ID: 20189234
[TBL] [Abstract][Full Text] [Related]
12. Beyond tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Shih KK; Chi DS; Barakat RR; Leitao MM
Gynecol Oncol; 2010 Mar; 116(3):364-9. PubMed ID: 19897231
[TBL] [Abstract][Full Text] [Related]
13. The incidence of major complications after the performance of extensive upper abdominal surgical procedures during primary cytoreduction of advanced ovarian, tubal, and peritoneal carcinomas.
Chi DS; Zivanovic O; Levinson KL; Kolev V; Huh J; Dottino J; Gardner GJ; Leitao MM; Levine DA; Sonoda Y; Abu-Rustum NR; Brown CL; Barakat RR
Gynecol Oncol; 2010 Oct; 119(1):38-42. PubMed ID: 20609464
[TBL] [Abstract][Full Text] [Related]
14. Improved survival for fallopian tube cancer: a comparison of clinical characteristics and outcome for primary fallopian tube and ovarian cancer.
Wethington SL; Herzog TJ; Seshan VE; Bansal N; Schiff PB; Burke WM; Cohen CJ; Wright JD
Cancer; 2008 Dec; 113(12):3298-306. PubMed ID: 19006196
[TBL] [Abstract][Full Text] [Related]
15. Influence of interval between primary surgery and chemotherapy on short-term survival of patients with advanced ovarian, tubal or peritoneal cancer.
Paulsen T; Kaern J; Kjaerheim K; Haldorsen T; Tropé C
Gynecol Oncol; 2006 Sep; 102(3):447-52. PubMed ID: 16516277
[TBL] [Abstract][Full Text] [Related]
16. The benefits of low anterior en bloc resection as part of cytoreductive surgery for advanced primary and recurrent epithelial ovarian cancer patients outweigh morbidity concerns.
Park JY; Seo SS; Kang S; Lee KB; Lim SY; Choi HS; Park SY
Gynecol Oncol; 2006 Dec; 103(3):977-84. PubMed ID: 16837030
[TBL] [Abstract][Full Text] [Related]
17. Prognosis of ovarian cancer subsequent to venous thromboembolism: a nationwide Danish cohort study.
Tetsche MS; Nørgaard M; Pedersen L; Lash TL; Sørensen HT
BMC Cancer; 2006 Jul; 6():189. PubMed ID: 16846496
[TBL] [Abstract][Full Text] [Related]
18. Intraperitoneal access via direct puncture is an alternative way to deliver intraperitoneal chemotherapy in ovarian, fallopian tube and primary peritoneal cancer.
Lan C; Li Y; Liu J
Gynecol Oncol; 2009 Jul; 114(1):42-7. PubMed ID: 19398124
[TBL] [Abstract][Full Text] [Related]
19. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer.
Eisenhauer EL; Abu-Rustum NR; Sonoda Y; Levine DA; Poynor EA; Aghajanian C; Jarnagin WR; DeMatteo RP; D'Angelica MI; Barakat RR; Chi DS
Gynecol Oncol; 2006 Dec; 103(3):1083-90. PubMed ID: 16890277
[TBL] [Abstract][Full Text] [Related]
20. Ovarian carcinosarcomas: clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum.
Cicin I; Saip P; Eralp Y; Selam M; Topuz S; Ozluk Y; Aydin Y; Topuz E
Gynecol Oncol; 2008 Jan; 108(1):136-40. PubMed ID: 17936342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
